Literature DB >> 4030923

Effects of enkephalins, morphine, and naloxone on pial arteries during perivascular microapplication.

M Wahl.   

Abstract

The effects of the opiate receptor agonists, enkephalins and morphine, and the antagonist, naloxone, on cerebrovascular resistance vessels was investigated in situ by employing perivascular microapplication. Feline pial arteries with a resting diameter of 66-294 micron were tested. Vascular diameter was measured using television image splitting. Concentration-response curves revealed no change of diameter when Leu-enkephalin, D-Ala2-Leu-enkephalinamide, D-Ala2-Met-enkephalinamide, and morphine were applied in concentrations of 10(-11)-10(-5) M. Considering the concentrations of enkephalins that have been found in natural cerebrospinal fluid or that can be expected in the vicinity of enkephalinergic synapses, the data obtained with the lower concentrations indicate that enkephalins are probably not important for the regulation of pial arterial resistance. At 10(-4) M only the dilation (4.3%) elicited by D-Ala2-Leu-enkephalinamide was statistically significant (p less than 0.01). All four agonists at 10(-3) M induced significant dilatations varying between 5.4 and 13.6%. Naloxone exerted no vascular effect per se at 10(-5) and 10(-4) M but a dilatation of 15.3% at 10(-3) M. The latter can be explained by a partial agonist action. During simultaneous administration, naloxone (10(-4) M) reduced the dilatations induced by 10(-4) and 10(-3) M D-Ala2-Leu-enkephalinamide dose dependently. This indicates that mu- and delta-opioid receptors, probably located at the vascular smooth muscle cell, were involved in the mediation of the dilatation induced by the highest concentrations of the compounds.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4030923     DOI: 10.1038/jcbfm.1985.61

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  5 in total

1.  CSF beta-endorphin and leu-enkephalin levels in the acute and chronic stages of cerebral infarction.

Authors:  M Kobari; N Ishihara; K Yunoki
Journal:  J Neurol       Date:  1987-06       Impact factor: 4.849

2.  A double blind randomized pilot trial of naloxone in the treatment of acute ischemic stroke.

Authors:  F Federico; V Lucivero; P Lamberti; A Fiore; C Conte
Journal:  Ital J Neurol Sci       Date:  1991-12

Review 3.  Adverse effects of opioid agonists and agonist-antagonists in anaesthesia.

Authors:  T A Bowdle
Journal:  Drug Saf       Date:  1998-09       Impact factor: 5.606

4.  The effect of morphine on regional cerebral blood flow measured by 99mTc-ECD SPECT in dogs.

Authors:  Antita Adriaens; Kathelijne Peremans; Tim Waelbers; Eva Vandermeulen; Siska Croubels; Luc Duchateau; André Dobbeleir; Kurt Audenaert; Jos Eersels; Simon Vermeire; Bart De Spiegeleer; Ingeborgh Polis
Journal:  PLoS One       Date:  2014-10-08       Impact factor: 3.240

5.  Refractory intracranial hypertension due to fentanyl administration following closed head injury.

Authors:  Sara E Hocker; Jeremy Fogelson; Alejandro A Rabinstein
Journal:  Front Neurol       Date:  2013-01-28       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.